ArticleBMC medical genomics2026
Cellular senescence in gastric cancer: a novel prognostic stratification and immune predictor.
Article in BMC medical genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Serum microRNA Profiles Reflect Differentiation Status and Age in Early Gastric Cancer.Biomolecules · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Cellular senescence, a state of permanent arrest of the cell cycle in response to various damage, exerts dual impact on tumor initiation and progression and has emerged as a promising therapeutic target. However, an applicable tool to quantify senescence remains exclusive. In this study, we investigated the role of senescence in gastric cancer (GC) progression through the analysis of TCGA-STAD cohort. According to senescence-associated gene (SAG) expression signatures, TCGA-STAD was divided into distinct senescence clusters. Cluster B with elevated expression of SAGs was associated with a poorer prognosis and a tumor microenvironment that was more conducive for tumor growth. Based on prognosis-associated differentially expressed genes (DEGs) between senescence clusters, we constructed cellular senescence score system (SSS) to quantify senescence of GC. SSS could serve as an independent prognostic factor and, notably, has the potential to identify patients who may benefit from immunotherapy. This indicates the strong potential of SSS as a biomarker for predicting immunotherapeutic response. In conclusion, SSS provides a reliable tool for prognosis prediction and treatment strategies for GC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.